XML 33 R10.htm IDEA: XBRL DOCUMENT
v3.19.3

Revenues | 9 Months Ended
--- | ---
Sep. 30, 2019
Revenue from Contract with Customer [Abstract] |
Revenues | REVENUES Disaggregation of Revenues The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):
|  | Three Months Ended September 30, 2019 |  | Three Months Ended September 30, 2018
|  | U.S. |  | Europe |  | Other Locations |  | Total |  | U.S. |  | Europe |  | Other Locations |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 132 |  |  | $ | 10 |  |  | $ | 7 |  |  | $ | 149 |  |  | $ | 221 |  |  | $ | 29 |  |  | $ | 8 |  |  | $ | 258 |
Biktarvy |  | 1,106 |  |  | 108 |  |  | 45 |  |  | 1,259 |  |  | 375 |  |  | 11 |  |  | — |  |  | 386 |
Complera/Eviplera |  | 40 |  |  | 45 |  |  | 8 |  |  | 93 |  |  | 61 |  |  | 67 |  |  | 11 |  |  | 139 |
Descovy |  | 256 |  |  | 63 |  |  | 44 |  |  | 363 |  |  | 310 |  |  | 81 |  |  | 15 |  |  | 406 |
Genvoya |  | 761 |  |  | 152 |  |  | 65 |  |  | 978 |  |  | 921 |  |  | 203 |  |  | 52 |  |  | 1,176 |
Odefsey |  | 317 |  |  | 111 |  |  | 8 |  |  | 436 |  |  | 323 |  |  | 95 |  |  | 5 |  |  | 423 |
Stribild |  | 63 |  |  | 18 |  |  | 13 |  |  | 94 |  |  | 111 |  |  | 20 |  |  | 15 |  |  | 146 |
Truvada |  | 688 |  |  | 14 |  |  | 19 |  |  | 721 |  |  | 665 |  |  | 62 |  |  | 30 |  |  | 757 |
Other HIV(1) |  | 3 |  |  | 1 |  |  | 1 |  |  | 5 |  |  | 10 |  |  | 2 |  |  | 2 |  |  | 14 |
Revenue share – Symtuza(2) |  | 68 |  |  | 36 |  |  | — |  |  | 104 |  |  | 8 |  |  | 14 |  |  | — |  |  | 22 |
AmBisome |  | 9 |  |  | 57 |  |  | 33 |  |  | 99 |  |  | 9 |  |  | 59 |  |  | 34 |  |  | 102 |
Ledipasvir/Sofosbuvir(3) |  | 54 |  |  | 14 |  |  | 56 |  |  | 124 |  |  | 185 |  |  | 38 |  |  | 88 |  |  | 311 |
Letairis |  | 121 |  |  | — |  |  | — |  |  | 121 |  |  | 241 |  |  | — |  |  | — |  |  | 241 |
Ranexa |  | 31 |  |  | — |  |  | — |  |  | 31 |  |  | 178 |  |  | — |  |  | — |  |  | 178 |
Sofosbuvir/Velpatasvir(4) |  | 282 |  |  | 118 |  |  | 116 |  |  | 516 |  |  | 225 |  |  | 136 |  |  | 116 |  |  | 477 |
Vemlidy |  | 78 |  |  | 6 |  |  | 50 |  |  | 134 |  |  | 66 |  |  | 2 |  |  | 19 |  |  | 87 |
Viread |  | 7 |  |  | 15 |  |  | 35 |  |  | 57 |  |  | 17 |  |  | 10 |  |  | 43 |  |  | 70 |
Vosevi |  | 42 |  |  | 12 |  |  | 9 |  |  | 63 |  |  | 78 |  |  | 21 |  |  | 4 |  |  | 103 |
Yescarta |  | 86 |  |  | 32 |  |  | — |  |  | 118 |  |  | 75 |  |  | — |  |  | — |  |  | 75 |
Zydelig |  | 13 |  |  | 13 |  |  | — |  |  | 26 |  |  | 15 |  |  | 4 |  |  | 1 |  |  | 20 |
Other(5) |  | 42 |  |  | (21 | ) |  | 4 |  |  | 25 |  |  | 37 |  |  | 19 |  |  | 8 |  |  | 64 |
Total product sales |  | 4,199 |  |  | 804 |  |  | 513 |  |  | 5,516 |  |  | 4,131 |  |  | 873 |  |  | 451 |  |  | 5,455 |
Royalty, contract and other revenues |  | 20 |  |  | 67 |  |  | 1 |  |  | 88 |  |  | 20 |  |  | 102 |  |  | 19 |  |  | 141 |
Total revenues |  | $ | 4,219 |  |  | $ | 871 |  |  | $ | 514 |  |  | $ | 5,604 |  |  | $ | 4,151 |  |  | $ | 975 |  |  | $ | 470 |  |  | $ | 5,596 |
|  | Nine Months Ended September 30, 2019 |  | Nine Months Ended September 30, 2018
|  | U.S. |  | Europe |  | Other Locations |  | Total |  | U.S. |  | Europe |  | Other Locations |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 387 |  |  | $ | 52 |  |  | $ | 33 |  |  | $ | 472 |  |  | $ | 723 |  |  | $ | 119 |  |  | $ | 79 |  |  | $ | 921 |
Biktarvy |  | 2,868 |  |  | 229 |  |  | 71 |  |  | 3,168 |  |  | 593 |  |  | 13 |  |  | — |  |  | 606 |
Complera/Eviplera |  | 126 |  |  | 179 |  |  | 26 |  |  | 331 |  |  | 210 |  |  | 279 |  |  | 39 |  |  | 528 |
Descovy |  | 735 |  |  | 200 |  |  | 128 |  |  | 1,063 |  |  | 895 |  |  | 234 |  |  | 41 |  |  | 1,170 |
Genvoya |  | 2,222 |  |  | 522 |  |  | 229 |  |  | 2,973 |  |  | 2,678 |  |  | 596 |  |  | 144 |  |  | 3,418 |
Odefsey |  | 865 |  |  | 328 |  |  | 27 |  |  | 1,220 |  |  | 905 |  |  | 230 |  |  | 15 |  |  | 1,150 |
Stribild |  | 208 |  |  | 60 |  |  | 30 |  |  | 298 |  |  | 388 |  |  | 83 |  |  | 36 |  |  | 507 |
Truvada |  | 1,896 |  |  | 88 |  |  | 61 |  |  | 2,045 |  |  | 1,821 |  |  | 245 |  |  | 108 |  |  | 2,174 |
Other HIV(1) |  | 23 |  |  | 3 |  |  | 11 |  |  | 37 |  |  | 30 |  |  | 6 |  |  | 10 |  |  | 46 |
Revenue share – Symtuza(2) |  | 165 |  |  | 89 |  |  | — |  |  | 254 |  |  | 8 |  |  | 34 |  |  | — |  |  | 42 |
AmBisome |  | 27 |  |  | 174 |  |  | 96 |  |  | 297 |  |  | 40 |  |  | 170 |  |  | 102 |  |  | 312 |
Ledipasvir/Sofosbuvir(3) |  | 257 |  |  | 63 |  |  | 222 |  |  | 542 |  |  | 649 |  |  | 116 |  |  | 225 |  |  | 990 |
Letairis |  | 522 |  |  | — |  |  | — |  |  | 522 |  |  | 689 |  |  | — |  |  | — |  |  | 689 |
Ranexa |  | 205 |  |  | — |  |  | — |  |  | 205 |  |  | 581 |  |  | — |  |  | — |  |  | 581 |
Sofosbuvir/Velpatasvir(4) |  | 731 |  |  | 428 |  |  | 341 |  |  | 1,500 |  |  | 733 |  |  | 502 |  |  | 278 |  |  | 1,513 |
Vemlidy |  | 214 |  |  | 15 |  |  | 122 |  |  | 351 |  |  | 172 |  |  | 8 |  |  | 41 |  |  | 221 |
Viread |  | 28 |  |  | 57 |  |  | 119 |  |  | 204 |  |  | 40 |  |  | 72 |  |  | 137 |  |  | 249 |
Vosevi |  | 140 |  |  | 43 |  |  | 18 |  |  | 201 |  |  | 250 |  |  | 57 |  |  | 12 |  |  | 319 |
Yescarta |  | 275 |  |  | 59 |  |  | — |  |  | 334 |  |  | 183 |  |  | — |  |  | — |  |  | 183 |
Zydelig |  | 36 |  |  | 42 |  |  | 1 |  |  | 79 |  |  | 46 |  |  | 44 |  |  | 2 |  |  | 92 |
Other(5) |  | 119 |  |  | 96 |  |  | 12 |  |  | 227 |  |  | 93 |  |  | 75 |  |  | 117 |  |  | 285 |
Total product sales |  | 12,049 |  |  | 2,727 |  |  | 1,547 |  |  | 16,323 |  |  | 11,727 |  |  | 2,883 |  |  | 1,386 |  |  | 15,996 |
Royalty, contract and other revenues |  | 61 |  |  | 181 |  |  | 5 |  |  | 247 |  |  | 54 |  |  | 233 |  |  | 49 |  |  | 336 |
Total revenues |  | $ | 12,110 |  |  | $ | 2,908 |  |  | $ | 1,552 |  |  | $ | 16,570 |  |  | $ | 11,781 |  |  | $ | 3,116 |  |  | $ | 1,435 |  |  | $ | 16,332 |
____________________
Notes:
(1) | Includes Emtriva and Tybost
(2) | Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC
(3) | Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC
(4) | Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC
(5) | Includes Cayston, Hepsera and Sovaldi. Europe product sales included unfavorable adjustments recorded in 2019 for statutory rebates related to sales of Sovaldi made in prior years
Revenues Recognized from Performance Obligations Satisfied in Prior Periods Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $201 million and $527 million for the three and nine months ended September 30, 2019, respectively, and $167 million and $395 million for the three and nine months ended September 30, 2018, respectively. Changes in estimates for variable consideration related to sales made in prior years resulted in a $9 million and $309 million increase in revenues for the three and nine months ended September 30, 2019, respectively. Changes in estimates for variable consideration related to sales made in prior years were not material for the three and nine months ended September 30, 2018, respectively. Contract Balances Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $160 million and $125 million as of September 30, 2019 and December 31, 2018, respectively. Contract liabilities were not material as of September 30, 2019 and December 31, 2018.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -URI http://asc.fasb.org/topic&trid=49130388 + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration